Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.

Significant unmet treatment needs remain for patients with Dravet syndrome, a severe ... global footprint,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen.

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ:STOK ...

Advocating for her youngest daughter who has Dravet Syndrome is also a top priority ... where she graduated from H-BC and grew up on a farm near Hills. In her spare time, Jennifer likes to read, watch ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

Study: Neonatal but not Juvenile Gene Therapy Reduces Seizures and Prolongs Lifespan in SCN1B-Dravet Syndrome Mice. Image Credit: Natali _ Mis/Shutterstock.com Developmental and epileptic ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...